

EARLY TERMINATIONS GRANTED—Continued

[February 1, 2026, through February 28, 2026]

20260736	G	Sanofi; Jian Peng; Sanofi.
20260744	G	Japan Petroleum Exploration Co., Ltd.; Verdad Resources Parent LLC; Japan Petroleum Exploration Co., Ltd.

02/11/2026

20260749	G	Hogan Lovells US LLP; Cadwalader, Wickersham & Taft LLP; Hogan Lovells US LLP.
20260752	G	Impala IGT NewCo Limited; Warburg Pincus Jovian GG, L.P.; Impala IGT NewCo Limited.
20260758	G	BioMarin Pharmaceutical Inc.; Amicus Therapeutics, Inc.; BioMarin Pharmaceutical Inc.
20260767	G	Eli Lilly and Company; Ventyx Biosciences, Inc.; Eli Lilly and Company.
20260771	G	American Water Works Company, Inc.; IIF US Holdings 2 LP; American Water Works Company, Inc.
20260775	G	New Mountain Partners VI, L.P.; New Mountain Partners VI Aggregator, L.P.
20260776	G	New Mountain Partners VI Aggregator, L.P.; New Mountain Partners VI, L.P.
20260784	G	Rite-Hite Holding Corporation Voting Trust; Randall L. Johnson; Rite-Hite Holding Corporation Voting Trust.

02/13/2026

20260714	G	Howard Hughes Holdings Inc.; Vantage Group Holdings Ltd.; Howard Hughes Holdings Inc.
20260730	G	Impact XM Holdings LLC; Omnicom Group Inc.; Impact XM Holdings LLC.
20260750	G	GT Silver Parent, LP; Clearwater Analytics Holdings, Inc.; GT Silver Parent, LP.
20260756	G	17567201 Canada Inc.; GDI Integrated Facility Services Inc.; 17567201 Canada Inc.
20260773	G	Sony Group Corporation; WildBrain Ltd.; Sony Group Corporation.
20260777	G	Boeing Employees' Credit Union; SAFE Credit Union; Boeing Employees' Credit Union.
20260793	G	Oracle Corporation; Applied Invention, LLC; Oracle Corporation.
20260799	G	Blackstone Capital Partners VIII L.P.; ON24, Inc.; Blackstone Capital Partners VIII L.P.
20260803	G	Ernesto Bertarelli; Ginger TopCo L.P.; Ernesto B.ertarelli
20260811	G	Kirin Holdings Company, Ltd.; Amgen Inc.; Kirin Holdings Company, Ltd.
20260813	G	U.S. Bancorp; Condor Trading, LP; U.S. Bancorp.
20260815	G	ISQ Global Infrastructure Fund IV, L.P.; Triton Fund IV L.P.; ISQ Global Infrastructure Fund IV, L.P.

02/24/2026

20260652	G	ProAmpac PPC Holdings LLC; Capinabel Inc.; ProAmpac PPC Holdings LLC.
20260822	G	TPG Partners VIII, L.P.; strongDM, Inc.; TPG Partners VIII, L.P.
20260830	G	AbbVie Inc.; RemeGen Co., Ltd.; AbbVie Inc.

FOR FURTHER INFORMATION CONTACT:

Theresa Kingsberry (phone: 202–326–3100), Program Support Specialist, Federal Trade Commission, Bureau of Competition, Premerger Notification Office, Room CC–5301, Washington, DC 20024.

By direction of the Commission.

Joel Christie,

Acting Secretary.

[FR Doc. 2026–04542 Filed 3–6–26; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day–26–0770]

Agency Forms Undergoing Paperwork Reduction Act Review

In accordance with the Paperwork Reduction Act of 1995, the Centers for Disease Control and Prevention (CDC) has submitted the information collection request titled “National HIV Behavioral Surveillance System (NHBS)” to the Office of Management and Budget (OMB) for review and

approval. CDC previously published a “Proposed Data Collection Submitted for Public Comment and Recommendations” notice on November 21, 2025 to obtain comments from the public and affected agencies. CDC received 10 comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments.

CDC will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that:

(a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Enhance the quality, utility, and clarity of the information to be collected;

(d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated,

electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and

(e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication.

Proposed Project

National HIV Behavioral Surveillance System (NHBS) (OMB Control No. 0920–0770, Exp. 4/30/2026)—Revision—National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The purpose of this data collection is to monitor behaviors of persons at high risk for infections that are related to Human Immunodeficiency Virus (HIV) transmission and prevention in the United States. The primary objectives of the NHBS are to obtain data from samples of persons at risk to: (a) describe the prevalence and trends in risk behaviors; (b) describe the prevalence of and trends in HIV testing and HIV infection; (c) describe the prevalence of and trends in use of HIV prevention services; and (d) identify met and unmet needs for HIV prevention services in order to inform health departments, community-based organizations, community planning groups and other partners.

By describing and monitoring the HIV risk behaviors, HIV seroprevalence and

incidence, and HIV prevention experiences of persons at highest risk for HIV infection, NHBS provides an important data source for evaluating progress towards national public health initiatives, such as reducing new infections, increasing the use of condoms, and targeting populations at high risk. The Centers for Disease Control and Prevention (CDC) requests approval for a three-year Revision of this information collection. Data are collected through in-person interviews conducted with persons systematically selected from 21 Metropolitan Statistical Areas (MSAs) throughout the United States. These 21 MSAs are chosen based on highest number of HIV infections diagnosed. Persons at risk for HIV infection to be interviewed for NHBS include men who have sex with men (MSM), persons who inject drugs (PWID), and heterosexually active persons at increased risk of HIV infection (HET). A brief screening interview will be used to determine eligibility for participation in the behavioral assessment.

The data from the behavioral assessment will provide estimates of: (1) behavior related to the risk of HIV and

other sexually transmitted diseases; (2) prior testing for HIV; and (3) use of HIV prevention services. All persons interviewed will also be offered an HIV test and will participate in a pre-test counseling session. No other federal agency systematically collects this type of information from persons at risk for HIV infection. These data have substantial impact on prevention program development and monitoring at the local, state, and national levels.

CDC estimates that each year NHBS will involve, eligibility screening for 125 persons and eligibility screening plus the behavioral assessment with 500 eligible respondents, in each of the 21 MSAs. Data collection will rotate such that interviews will be conducted among one group per year: MSM in Year 1, PWID in Year 2, and HET in Year 3. The type of data collected for each group will vary slightly due to different sampling methods and risk characteristics of the group. CDC requests OMB approval for an estimated 3,399 annual burden hours. Participation of respondents is voluntary and there is no cost to the respondents other than their time.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Persons Screened	Eligibility Screener	13,125	1	3/60
Eligible Participants	Behavioral Assessment MSM	3,500	1	13/60
Eligible Participants	Behavioral Assessment PWID	3,500	1	17/60
Eligible Participant	Behavioral Assessment HET	3,500	1	15/60
Peer Recruiters	Recruiter Debriefing	3,500	1	2/60

Jeffrey M. Zirger,

Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention.

[FR Doc. 2026–04561 Filed 3–6–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention**

[60Day–26–0222; Docket No. CDC–2026–0331]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice with comment period.

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled the Collaborating Center for Questionnaire Design and Evaluation Research (CCQDER). This Generic Clearance request encompasses general questionnaire development, pre-testing, and measurement-error reduction activities to be carried out in 2026–2029.

DATES: CDC must receive written comments on or before May 8, 2026.

ADDRESSES: You may submit comments, identified by Docket No. CDC–2026–0331 by either of the following methods:

- **Federal eRulemaking Portal:** www.regulations.gov. Follow the instructions for submitting comments.
- **Mail:** Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H21–8, Atlanta, Georgia 30329.

Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to www.regulations.gov.

Please note: Submit all comments through the Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the address listed above.